Filgrastim HEXAL
Granulocyte Colony-Stimulating Factor (G-CSF) — Biosimilar filgrastim for neutropenia management and stem cell mobilization
Filgrastim HEXAL is a biosimilar granulocyte colony-stimulating factor (G-CSF) containing recombinant human filgrastim. It stimulates the bone marrow to produce more neutrophils, the white blood cells that fight bacterial infections. Filgrastim HEXAL is primarily used to reduce the duration and severity of neutropenia following chemotherapy, to mobilize stem cells for transplantation, and to treat severe chronic neutropenia. This medication is administered by subcutaneous injection or intravenous infusion under medical supervision.
Quick Facts
Key Takeaways
- Filgrastim HEXAL is a biosimilar G-CSF that stimulates white blood cell production in the bone marrow to fight infections during chemotherapy
- The most common side effect is musculoskeletal pain (bone pain), which typically responds to standard analgesics like paracetamol
- Must not be given within 24 hours before or after cytotoxic chemotherapy to avoid amplifying myelosuppression
- Requires refrigerated storage at 2–8°C but can be kept at room temperature (up to 25°C) for up to 72 hours before use
- Regular blood count monitoring, including white blood cell differential, is essential throughout treatment
What Is Filgrastim HEXAL and What Is It Used For?
Filgrastim HEXAL belongs to the class of medicines known as granulocyte colony-stimulating factors (G-CSFs). These biological medicines work by binding to specific receptors on the surface of neutrophil precursor cells in the bone marrow, triggering a cascade of cellular signals that promote the rapid production, maturation, and release of neutrophils into the bloodstream. Neutrophils are the most abundant type of white blood cell and serve as the body's primary defense against bacterial and fungal infections.
This medicine is a biosimilar, meaning it is a biological medicine that has been developed to be highly similar to an already authorized biological medicine known as the reference product (Neupogen). Biosimilars undergo extensive analytical, preclinical, and clinical comparability studies to demonstrate that they have no clinically meaningful differences from the reference product in terms of quality, safety, and efficacy. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have both established rigorous regulatory pathways for the approval of biosimilar medicines.
Filgrastim itself is produced by recombinant DNA technology in Escherichia coli bacteria. The resulting protein is a 175-amino acid polypeptide that is structurally identical to endogenous human G-CSF, with the exception of an additional N-terminal methionine residue and the absence of glycosylation. Despite these minor differences, the biological activity of filgrastim is clinically equivalent to that of the naturally occurring cytokine.
Approved Indications
Filgrastim HEXAL is approved for several clinical indications, each supported by robust evidence from randomized controlled trials and systematic reviews:
- Chemotherapy-induced neutropenia: Reduction in the duration and incidence of febrile neutropenia in patients receiving myelosuppressive anticancer chemotherapy. This is the most common indication and is supported by multiple meta-analyses demonstrating significant reductions in infection-related hospitalizations and mortality.
- Peripheral blood stem cell (PBSC) mobilization: Mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis and subsequent autologous or allogeneic stem cell transplantation. Filgrastim is typically administered for 4–6 days before stem cell collection.
- Bone marrow transplantation: Acceleration of neutrophil recovery following myeloablative therapy and bone marrow transplantation, reducing the risk of life-threatening infections during the engraftment period.
- Severe chronic neutropenia (SCN): Long-term treatment of congenital, cyclic, or idiopathic neutropenia to increase neutrophil counts and reduce the frequency and duration of infection-related events. Patients with severe chronic neutropenia often require lifelong treatment.
- HIV-associated neutropenia: Treatment of persistent neutropenia in patients with advanced HIV infection to reduce the risk of bacterial infections.
The choice to prescribe Filgrastim HEXAL is typically made by oncologists, hematologists, or specialists in infectious disease, and treatment is initiated and monitored under close medical supervision. The specific indication determines the dosing regimen, duration of treatment, and monitoring requirements.
What Should You Know Before Taking Filgrastim HEXAL?
Before beginning treatment with Filgrastim HEXAL, your healthcare provider will conduct a thorough evaluation of your medical history and current health status. It is essential that you provide complete information about all medications you are taking, any allergies you have, and any pre-existing medical conditions, as these factors can significantly influence whether filgrastim is appropriate for you and how it should be monitored.
Contraindications
Filgrastim HEXAL must not be used in patients with known hypersensitivity to filgrastim, to any of the excipients, or to proteins derived from Escherichia coli. Allergic reactions, including anaphylaxis, have been reported in post-marketing surveillance, though they are rare. If a serious allergic reaction occurs, treatment must be discontinued immediately and appropriate medical treatment administered.
Filgrastim should not be used to increase the dose-intensity of chemotherapy beyond established dose regimens, as G-CSF does not reduce the toxicity of chemotherapy agents to non-myeloid tissues. Using filgrastim to support higher chemotherapy doses than those proven safe may result in increased non-hematological toxicity, including cardiac, pulmonary, neurological, and dermatological adverse effects.
Warnings and Precautions
Several important warnings and precautions apply to the use of Filgrastim HEXAL. Your doctor should be aware of the following conditions and risk factors:
- Splenic rupture: Cases of splenic rupture, including fatal cases, have been reported following administration of G-CSF. Patients receiving filgrastim who report left upper abdominal or shoulder tip pain should be evaluated urgently for splenic enlargement or rupture.
- Acute respiratory distress syndrome (ARDS): ARDS has been reported in patients receiving G-CSF. Patients who develop fever, lung infiltrates, or respiratory distress should be evaluated for ARDS, and filgrastim should be discontinued if ARDS develops.
- Sickle cell crisis: Severe and sometimes fatal sickle cell crises have occurred in patients with sickle cell disease receiving G-CSF. Physicians should use extreme caution when considering filgrastim in patients with sickle cell trait or sickle cell disease.
Additional precautions include monitoring for capillary leak syndrome, which is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Patients with a history of capillary leak syndrome should be closely monitored, and filgrastim should be used with caution in this population. Glomerulonephritis has also been reported in patients receiving filgrastim, typically resolving after dose reduction or discontinuation.
In patients with severe chronic neutropenia (SCN), there is an inherent risk of developing myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). This risk exists independently of G-CSF treatment but is important to consider during long-term therapy. Regular cytogenetic evaluation and monitoring of peripheral blood smears is recommended for SCN patients receiving long-term filgrastim.
Filgrastim can cause transient decreases in blood pressure, which rarely require therapeutic intervention. However, blood pressure monitoring is recommended, particularly during the initial doses. Increased hematopoietic activity in the bone marrow in response to G-CSF therapy has been associated with transient positive bone-imaging findings, which should be considered when interpreting bone-imaging results.
Pregnancy and Breastfeeding
There are limited data on the use of filgrastim in pregnant women. Animal reproduction studies have shown adverse effects on the developing fetus, including increased embryo-fetal mortality and decreased fetal weight at doses significantly higher than the human therapeutic dose. The potential risk to human pregnancies is not fully characterized. Filgrastim HEXAL should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus, and this decision should be made in careful consultation with the treating physician.
It is not known whether filgrastim or its metabolites are excreted in human breast milk. A risk to the breastfed infant cannot be excluded. A decision should be made whether to discontinue breastfeeding or to discontinue filgrastim therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Women of childbearing potential should use effective contraception during treatment with Filgrastim HEXAL.
How Does Filgrastim HEXAL Interact with Other Drugs?
Drug interactions with filgrastim are primarily related to its mechanism of action and its use in the context of cancer chemotherapy. The timing of filgrastim administration relative to chemotherapy is particularly critical, as giving filgrastim too close to myelosuppressive agents can paradoxically worsen neutropenia by stimulating the proliferation of myeloid precursors that are then more susceptible to the cytotoxic effects of chemotherapy.
Healthcare providers managing patients on filgrastim should be aware of both pharmacodynamic and pharmacokinetic interactions. While filgrastim has few direct pharmacokinetic interactions (it does not significantly affect hepatic enzyme systems), its pharmacodynamic interactions with agents that affect myeloid cell proliferation are clinically significant and can impact treatment outcomes.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| 5-Fluorouracil (5-FU) | Severe neutropenia when filgrastim is given within 24 hours of 5-FU; rapidly dividing myeloid progenitors become more sensitive to cytotoxic agents | Do not administer filgrastim within 24 hours before or after 5-FU administration |
| Other myelosuppressive chemotherapy | Same mechanism as 5-FU; potential for enhanced myelosuppression if given concurrently | Administer filgrastim at least 24 hours after the last dose of chemotherapy; discontinue at least 24 hours before the next cycle |
| Bleomycin | Potential increased pulmonary toxicity when used with G-CSF; cases of pneumonitis reported | Monitor pulmonary function closely; consider risk-benefit ratio |
Minor Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Lithium | Lithium promotes release of neutrophils; may potentiate the effect of filgrastim on white blood cell counts | Monitor white blood cell counts more frequently if used concurrently |
| Corticosteroids | Corticosteroids can cause neutrophilia through demargination; may confound interpretation of WBC response to filgrastim | Account for steroid-induced neutrophilia when interpreting blood counts |
| Topotecan | Prolonged duration of neutropenia when filgrastim is given on the same day as topotecan | Administer filgrastim at least 24 hours after completion of topotecan |
Always inform your healthcare team about all medications, supplements, and herbal products you are taking. This includes over-the-counter medicines, vitamins, and nutritional supplements. Your doctor or pharmacist can help identify potential interactions and adjust your treatment plan accordingly.
What Is the Correct Dosage of Filgrastim HEXAL?
The dosage of Filgrastim HEXAL is individualized based on the specific clinical indication, body weight, and the patient's response to treatment. All dosing decisions should be made by qualified healthcare professionals experienced in the management of the underlying condition. The following dosing guidelines are based on international consensus recommendations and product labeling approved by the EMA and FDA.
Adults
Chemotherapy-Induced Neutropenia
The recommended dose is 5 mcg/kg/day (0.5 MU/kg/day) administered as a single daily subcutaneous injection. Treatment should begin no earlier than 24 hours after the completion of chemotherapy and should continue until the expected neutrophil nadir has been passed and the neutrophil count has recovered to the normal range. Treatment for up to 14 days may be necessary following each chemotherapy cycle. The dose may be increased to 10 mcg/kg/day if the neutrophil response is suboptimal.
Peripheral Blood Stem Cell Mobilization
For stem cell mobilization in patients undergoing autologous transplantation, the recommended dose is 10 mcg/kg/day (1.0 MU/kg/day) administered by subcutaneous injection for 4–6 consecutive days. Leukapheresis is typically performed on days 5 and 6. In some protocols, the dose may be adjusted based on CD34+ cell counts in the peripheral blood. When used for mobilization after myelosuppressive chemotherapy, a dose of 5 mcg/kg/day is initiated the day after chemotherapy completion and continued until the last leukapheresis session.
Bone Marrow Transplantation
The recommended dose following myeloablative therapy and bone marrow transplantation is 10 mcg/kg/day (1.0 MU/kg/day) administered as a 30-minute or 24-hour intravenous infusion, or as a continuous 24-hour subcutaneous infusion. The first dose should be administered no earlier than 24 hours after cytotoxic chemotherapy or bone marrow infusion. Treatment duration is adjusted based on neutrophil recovery, with a maximum recommended duration of 28 days.
Severe Chronic Neutropenia
For congenital neutropenia, the recommended starting dose is 12 mcg/kg/day (1.2 MU/kg/day) administered as a single daily subcutaneous injection or divided into multiple doses. For idiopathic or cyclic neutropenia, the starting dose is 5 mcg/kg/day (0.5 MU/kg/day). The dose is then adjusted individually to maintain a target absolute neutrophil count (ANC) of 1.5–10.0 × 109/L. The minimum effective dose should be used for long-term maintenance.
Children
Filgrastim HEXAL is used in pediatric patients across all approved indications. The dosing in children is generally the same as in adults on a weight-based (mcg/kg/day) basis. For chemotherapy-induced neutropenia in children, the standard dose of 5 mcg/kg/day is recommended. For severe congenital neutropenia in children, higher doses may be required, and dose adjustments should be guided by regular monitoring of absolute neutrophil counts. The safety and efficacy of filgrastim in neonates and infants have not been extensively studied, and use in this population should be under close specialist supervision.
Elderly
No specific dose adjustments are recommended for elderly patients. However, elderly patients may be more susceptible to side effects, particularly musculoskeletal pain and fatigue. Clinical trials of filgrastim in elderly cancer patients have demonstrated similar efficacy and safety profiles to those observed in younger adults. As with all patients, dosing should be guided by clinical response and blood count monitoring, with particular attention to renal function since age-related decline in renal clearance may affect drug elimination.
Missed Dose
If a dose of Filgrastim HEXAL is missed, contact your healthcare provider for guidance. In general, a missed dose should be administered as soon as remembered, unless it is close to the time of the next scheduled dose. Do not administer a double dose to compensate for a missed dose. Missing individual doses during a treatment course may reduce the effectiveness of the neutrophil recovery, so maintaining the prescribed dosing schedule as closely as possible is important. If you forget a dose, your doctor may recommend adjusting the treatment duration rather than doubling up on doses.
Overdose
There is limited clinical experience with filgrastim overdose. In cases of overdose, white blood cell counts may rise to very high levels (leukocytosis), which generally reverses within 1–2 days after discontinuation. White blood cell counts above 100 × 109/L have been observed without directly attributable adverse effects, though the risks of such marked leukocytosis include hyperviscosity and leukostasis, which could lead to pulmonary infiltrates or cerebral complications. Treatment of overdose is supportive and involves discontinuation of filgrastim with close monitoring of blood counts. There is no specific antidote for filgrastim.
What Are the Side Effects of Filgrastim HEXAL?
Like all medicines, Filgrastim HEXAL can cause side effects, although not everybody gets them. The side effect profile has been well characterized through extensive clinical trials and post-marketing surveillance data spanning more than two decades of clinical use of filgrastim products worldwide. Most side effects are mild to moderate in severity and resolve upon dose reduction or discontinuation of treatment.
It is important to distinguish between side effects that occur in the context of chemotherapy (where many symptoms may be attributable to the underlying cancer or the chemotherapy itself rather than to filgrastim) and those observed in healthy donors undergoing stem cell mobilization or in patients with severe chronic neutropenia. The following frequency classifications are based on pooled clinical trial data and pharmacovigilance reports, using the standard MedDRA frequency convention.
Very Common
Affects more than 1 in 10 patients (>10%)
- Musculoskeletal pain (bone pain, myalgia, arthralgia, back pain, pain in extremities)
- Headache
- Nausea
- Elevated lactate dehydrogenase (LDH)
- Elevated alkaline phosphatase
- Thrombocytopenia (in cancer patients receiving chemotherapy)
- Alopecia (in cancer patients receiving chemotherapy)
Common
Affects 1 to 10 in 100 patients (1–10%)
- Injection site reactions (pain, redness, swelling at the injection site)
- Elevated gamma-glutamyltransferase (GGT) and transaminases (AST, ALT)
- Epistaxis (nosebleeds)
- Diarrhea
- Splenomegaly (enlarged spleen)
- Fatigue and asthenia
- Hyperuricemia (elevated uric acid)
- Chest pain (non-cardiac)
Uncommon
Affects 1 to 10 in 1,000 patients (0.1–1%)
- Allergic reactions (rash, urticaria, angioedema)
- Cutaneous vasculitis (including Sweet syndrome)
- Proteinuria and hematuria
- Vascular disorders (hypotension, transient blood pressure changes)
- Aortitis (inflammation of the aorta)
- Pulmonary adverse events (cough, dyspnea)
Rare
Affects fewer than 1 in 1,000 patients (<0.1%)
- Splenic rupture (potentially fatal — seek immediate medical attention for left upper abdominal or shoulder pain)
- Acute respiratory distress syndrome (ARDS)
- Capillary leak syndrome (hypotension, hypoalbuminemia, edema)
- Sickle cell crisis in patients with sickle cell disease
- Anaphylaxis
- Glomerulonephritis
- Stevens-Johnson syndrome (very rare)
Bone pain is the most frequently reported side effect of filgrastim and results from the expansion of the bone marrow as it produces increased numbers of neutrophils. It is typically mild to moderate and most commonly affects the lower back, pelvis, and long bones. Standard analgesics such as paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are usually effective. In most cases, bone pain diminishes with continued treatment. If pain is severe or persistent, consult your healthcare provider, as dose adjustment may be considered.
If you experience any side effects, including those not listed above, talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national pharmacovigilance authority. Reporting helps to gather more information about the safety of this medicine.
How Should You Store Filgrastim HEXAL?
Proper storage of Filgrastim HEXAL is essential to maintain the integrity and efficacy of this biological medicine. As a protein-based product, filgrastim is sensitive to temperature extremes, light exposure, and physical agitation, all of which can lead to protein denaturation and loss of biological activity.
The pre-filled syringes should be stored in a refrigerator at 2–8°C (36–46°F). Do not freeze the product. If accidental freezing occurs, the syringe should be discarded and not used, as freezing can cause irreversible damage to the protein structure and lead to aggregation, which may increase the risk of immunogenicity or reduce efficacy. Keep the pre-filled syringes in the original outer carton to protect them from light.
For patient convenience, Filgrastim HEXAL may be removed from the refrigerator and stored at room temperature (not above 25°C / 77°F) for a single continuous period of up to 72 hours. If the product is not used within this 72-hour period, it must be discarded. Do not return the product to the refrigerator after it has been stored at room temperature. This room-temperature storage allowance is intended to facilitate home administration and is based on stability studies demonstrating that the product maintains its quality within this timeframe.
Keep this medicine out of the sight and reach of children. Do not use Filgrastim HEXAL after the expiry date stated on the carton and the pre-filled syringe label. The expiry date refers to the last day of that month. Before use, visually inspect the solution. It should be a clear, colorless liquid. Do not use the solution if it is cloudy, contains particles, or is discolored. Do not shake the syringe vigorously, as this may cause protein aggregation.
Used syringes and any unused medicine should be disposed of in accordance with local requirements for sharps disposal. Do not throw away syringes in household waste. Ask your pharmacist how to dispose of medicines you no longer use to help protect the environment.
What Does Filgrastim HEXAL Contain?
Understanding the full composition of Filgrastim HEXAL is important for identifying potential allergens and ensuring safe administration. The active substance and excipients have been carefully selected to maintain the stability and biological activity of the recombinant protein throughout the product's shelf life.
Active Substance
Each 0.5 mL pre-filled syringe contains 30 million units (MU) of filgrastim, equivalent to 300 micrograms (mcg). Filgrastim is a recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF) produced in genetically modified Escherichia coli (K12 strain) using recombinant DNA technology. The protein consists of 175 amino acids with a molecular weight of approximately 18,800 daltons.
Excipients
The inactive ingredients in Filgrastim HEXAL serve to stabilize the protein, maintain the appropriate pH, and prevent degradation during storage:
- Glutamic acid: Used as a buffering agent to maintain the pH of the solution at approximately 4.0, which is optimal for filgrastim stability
- Polysorbate 80: A non-ionic surfactant that prevents protein adsorption to container surfaces and reduces the risk of protein aggregation
- Sorbitol (E420): Functions as a tonicity agent and stabilizer. Patients with hereditary fructose intolerance should be aware that this product contains sorbitol
- Sodium hydroxide and/or hydrochloric acid: Used for pH adjustment as needed during manufacturing
- Water for injections: Serves as the solvent
Filgrastim HEXAL does not contain preservatives. Each pre-filled syringe is intended for single use only. Any unused portion of the solution should be discarded after use. The product is latex-free, and the syringe needle shield does not contain natural rubber latex, making it suitable for use in patients with latex allergy.
Frequently Asked Questions About Filgrastim HEXAL
Filgrastim HEXAL is a biosimilar granulocyte colony-stimulating factor (G-CSF) used to reduce the duration and severity of neutropenia (low white blood cell count) following myelosuppressive chemotherapy. It is also approved for mobilization of peripheral blood stem cells for autologous transplantation, acceleration of neutrophil recovery after bone marrow transplantation, treatment of severe chronic neutropenia (congenital, cyclic, or idiopathic), and reduction of infection risk in patients with advanced HIV infection and neutropenia.
Filgrastim HEXAL is administered as a subcutaneous (under the skin) injection or as an intravenous infusion. For most indications, subcutaneous injection is the preferred route. The pre-filled syringe contains 30 MU (300 mcg) in 0.5 mL. After appropriate training, patients or their caregivers can self-administer subcutaneous injections at home. Common injection sites include the abdomen (avoiding the area around the navel), upper thigh, or upper arm. Rotate injection sites to minimize injection site reactions.
The most common side effect is musculoskeletal pain, including bone pain, myalgia (muscle pain), and arthralgia (joint pain), which occurs in more than 10% of patients. This is caused by the expansion of bone marrow as it produces more neutrophils. Headache, nausea, and injection site reactions are also common. Most side effects are mild to moderate and can be managed with standard analgesics such as paracetamol or ibuprofen. Serious but rare side effects include splenic rupture and acute respiratory distress syndrome (ARDS).
Yes, Filgrastim HEXAL is a biosimilar to the reference product Neupogen (filgrastim). Biosimilars are biological medicines that have been shown through extensive comparative studies to be highly similar to an already authorized reference product, with no clinically meaningful differences in quality, safety, or efficacy. Filgrastim HEXAL underwent rigorous analytical, preclinical, and clinical testing before receiving approval from the European Medicines Agency (EMA) and other regulatory authorities. It offers the same therapeutic benefits as the reference product.
Filgrastim HEXAL should not be used during pregnancy unless clearly necessary and the potential benefit justifies the potential risk to the fetus. Animal studies have shown reproductive toxicity at high doses. There are limited data from pregnant women. It is unknown whether filgrastim is excreted in human breast milk, so breastfeeding is not recommended during treatment. Women of childbearing potential should use effective contraception during treatment. Decisions regarding use in pregnancy or breastfeeding should always be made in consultation with the treating physician.
Store Filgrastim HEXAL in the refrigerator at 2–8°C. Do not freeze. Keep the pre-filled syringes in the outer carton to protect from light. If needed, you may remove the syringe from the refrigerator and keep it at room temperature (up to 25°C) for a single period of no more than 72 hours. If it is not used within this time, it must be discarded — do not return it to the refrigerator. Always check the solution before use: it should be clear and colorless with no particles.
References
This article is based on the following peer-reviewed sources and international guidelines:
- European Medicines Agency (EMA). Filgrastim HEXAL – Summary of Product Characteristics (SmPC). EMA/CHMP, current version. Available at: www.ema.europa.eu
- Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 2015;33(28):3199–3212.
- Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia. European Journal of Cancer. 2011;47(1):8–32.
- Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–237.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 1.2025.
- Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111–5117.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- Dale DC, Bolyard AA, Schwinzer BG, et al. The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. Supportive Cancer Therapy. 2006;3(4):220–231.
- British National Formulary (BNF). Filgrastim. NICE Evidence Services, current edition. Available at: bnf.nice.org.uk
- Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. Journal of Clinical Oncology. 2007;25(21):3158–3167.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, composed of licensed specialist physicians with expertise in clinical pharmacology, hematology, and oncology.
iMedic Medical Editorial Team — specialists in clinical pharmacology and hematology with documented academic background and clinical experience in chemotherapy supportive care.
iMedic Medical Review Board — independent panel of medical experts reviewing all content according to international guidelines (WHO, EMA, FDA, ASCO, ESMO, NCCN).
Evidence standard: All medical claims in this article are supported by evidence level 1A (systematic reviews and meta-analyses of randomized controlled trials) or current international clinical practice guidelines. This content has no commercial funding and is free from pharmaceutical industry influence.